期刊文献+

重症病人应用万古霉素的药学服务典型案例解析 被引量:3

Typical case analysis of pharmaceutical care of critical patients treated with vancomycin
下载PDF
导出
摘要 目的:探讨重症病人使用万古霉素的药学服务要点。方法:通过万古霉素药学服务实践,解析典型案例,并进行归纳与总结。结果:临床药师对重症病人万古霉素使用的药学服务实践,可以从万古霉素初始给药方案的制定、方案调整与优化、血药浓度异常波动的原因分析、药品不良反应鉴别与处理等方面去实施。药师与医师、护士及时沟通能够确保临床用药的精准有效。结论:万古霉素的药学服务包括给药方案制定、调整与优化,以及血药浓度监测和药品不良反应的处理。 Objective:To investigate the main problems in pharmaceutical care of critical patients treated with vancomycin.Methods:A typical case was analyzed and summarized through pharmaceutical care and practice in the use of vancomycin.Results:Pharmaceutical care and practice by clinical pharmacists in the care of critical patients could be implemented by the following procedures:the development,adjustment and optimization of initial vancomycin medication profiles,analysis of abnormal fluctuation of serum drug concentration,and the identification and management of adverse drug reactions.In-time communication between pharmacists,physicians and nurses could ensure accurate and effective use of drugs clinically.Conclusion:Pharmaceutical care in the medication of vancomycin included development,adjustment and optimization of medication profiles,monitoring of serum drug concentration and management of adverse drug reactions.
出处 《药学服务与研究》 CAS 2018年第1期58-62,共5页 Pharmaceutical Care and Research
关键词 重症病人 万古霉素 药学服务 critical patients vancomycin pharmaceutical care
  • 相关文献

参考文献6

二级参考文献58

  • 1陈燕琴,宋萍.万古霉素静滴致小儿红人综合征1例报道[J].浙江预防医学,2009,21(2). 被引量:7
  • 2楚立云,李建成,周春.万古霉素不良反应[J].中国误诊学杂志,2006,6(14):2853-2853. 被引量:4
  • 3官东秀,俸小平,冯祚臻.万古霉素不良反应文献分析[J].中国药业,2007,16(1):42-43. 被引量:24
  • 4Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing~ twentieth informational supplement[S]. CLSI, M100-S20,2010.
  • 5Anton YP, Harald S, David LP. Acinetobacteraumannii: Emergence of a Successful Pathogen[J]. Clinical Microbiology Reviews, 2008,21 (3): 538-582.
  • 6Clinical and Laboratory Standards Institute.Performancestandards for antimicrobial susceptibility testing[S].CLSI,2010.
  • 7Wei ZQ,Du XX,Yu YS,et al.Plasmid-mediated KPC-2in a Klebsiella pneumoniae isolate from China[J].Antimicrob A-gents Chemother,2007,51(2):763-765.
  • 8Cai JC,Zhou HW,Zhang R,et al.Emergence of Serratia marcescens,Klebsiella pneumoniae,and Escherichia coli Iso-lates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2in intensive care units of a Chinese hos-pital[J].Antimicrob Agents Chemother,2008,52(6):2014-2018.
  • 9Shen P,Wei Z,Jiang Y,et al.Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2among En-terobacteriaceae in China[J].Antimicrob Agents Chemother,2009,53(10):4333-4338.
  • 10Fu Y,Zhou J,Zhou H,et al.Wide dissemination of OXA-23-producing carbapenem-resistant Acinetobacter baumannii clonal complex22in multiple cities of China[J].Antimicrob Chemother,2010,65(4):644-650.

共引文献859

同被引文献32

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部